BRPI0507476B8 - monoidrato cristalino, sua composição farmacêutica e seu uso - Google Patents
monoidrato cristalino, sua composição farmacêutica e seu usoInfo
- Publication number
- BRPI0507476B8 BRPI0507476B8 BRPI0507476A BRPI0507476A BRPI0507476B8 BR PI0507476 B8 BRPI0507476 B8 BR PI0507476B8 BR PI0507476 A BRPI0507476 A BR PI0507476A BR PI0507476 A BRPI0507476 A BR PI0507476A BR PI0507476 B8 BRPI0507476 B8 BR PI0507476B8
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline
- pharmaceutical composition
- crystalline monohydrate
- monohydrate
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54249004P | 2004-02-06 | 2004-02-06 | |
US60/542,490 | 2004-02-06 | ||
US62493704P | 2004-11-04 | 2004-11-04 | |
US60/624,937 | 2004-11-04 | ||
PCT/US2005/003728 WO2005077945A2 (en) | 2004-02-06 | 2005-02-04 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0507476A BRPI0507476A (pt) | 2007-07-17 |
BRPI0507476B1 BRPI0507476B1 (pt) | 2020-12-08 |
BRPI0507476B8 true BRPI0507476B8 (pt) | 2021-05-25 |
Family
ID=34864498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507476A BRPI0507476B8 (pt) | 2004-02-06 | 2005-02-04 | monoidrato cristalino, sua composição farmacêutica e seu uso |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1711481B2 (pt) |
JP (2) | JP5148115B2 (pt) |
KR (2) | KR101310427B1 (pt) |
AR (1) | AR047533A1 (pt) |
AT (1) | ATE453630T1 (pt) |
AU (1) | AU2005212405B2 (pt) |
BR (1) | BRPI0507476B8 (pt) |
CA (1) | CA2555291C (pt) |
CY (1) | CY1109907T1 (pt) |
DE (1) | DE602005018601D1 (pt) |
DK (1) | DK1711481T4 (pt) |
ES (1) | ES2337272T5 (pt) |
GE (1) | GEP20094804B (pt) |
HK (1) | HK1091835A1 (pt) |
HR (1) | HRP20100166T4 (pt) |
IL (1) | IL177280A (pt) |
IN (1) | IN2014DN06567A (pt) |
NO (1) | NO338049B1 (pt) |
NZ (1) | NZ548613A (pt) |
PE (1) | PE20050691A1 (pt) |
PL (1) | PL1711481T5 (pt) |
PT (1) | PT1711481E (pt) |
RU (1) | RU2382039C2 (pt) |
SI (1) | SI1711481T2 (pt) |
TW (1) | TWI338004B (pt) |
WO (1) | WO2005077945A2 (pt) |
ZA (1) | ZA200606242B (pt) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248906A1 (en) | 2001-08-10 | 2004-12-09 | Donato Nicholas J | Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia |
BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
WO2006121742A2 (en) * | 2005-05-05 | 2006-11-16 | Bristol-Myers Squibb Company | Formulations of a src/abl inhibitor |
WO2007019210A1 (en) * | 2005-08-05 | 2007-02-15 | Bristol-Myers Squibb Company | Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives |
US20070105867A1 (en) * | 2005-09-21 | 2007-05-10 | Bristol-Myers Squibb Company | Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
US20070219370A1 (en) * | 2006-03-15 | 2007-09-20 | Bristol-Myers Squibb Company | Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof |
AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
PL2508523T5 (pl) | 2007-10-23 | 2020-08-10 | Teva Pharmaceutical Industries Ltd. | Odmiany polimorficzne dasatynibu i sposób ich wytwarzania |
WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010067374A2 (en) * | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
JP5620979B2 (ja) * | 2009-05-05 | 2014-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | P38キナーゼ阻害剤 |
CN101812060B (zh) * | 2010-02-02 | 2011-08-17 | 南京卡文迪许生物工程技术有限公司 | 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物 |
EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
JP5589097B2 (ja) * | 2010-02-08 | 2014-09-10 | 南京▲か▼文迪許生物工程技術有限公司 | ダサチニブ多結晶体、並びにその調製方法及び薬物組成物 |
CN102250084A (zh) * | 2010-02-08 | 2011-11-23 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
WO2013065063A1 (en) | 2011-11-03 | 2013-05-10 | Cadila Healthcare Limited | Anhydrous form of dasatinib, process for its preparation and its use |
KR20150020683A (ko) | 2012-06-15 | 2015-02-26 | 바스프 에스이 | 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정 |
CN102827156A (zh) * | 2012-09-11 | 2012-12-19 | 湖南欧亚生物有限公司 | 一种达沙替尼的新的工业合成方法 |
CN103819469A (zh) * | 2012-11-16 | 2014-05-28 | 重庆医药工业研究院有限责任公司 | 一种达沙替尼的晶型及其制备方法 |
CZ306598B6 (cs) | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
CN103880833B (zh) * | 2012-12-19 | 2018-04-06 | 北京本草天源药物研究院 | 达沙替尼一水合物的新晶形及其制备方法和药物组合物 |
WO2014102759A2 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Process for the preparation of dasatinib and its intermediates |
CN103319476B (zh) * | 2013-06-13 | 2015-12-02 | 济南德爱医药技术有限公司 | 一种激酶抑制剂 |
KR101831535B1 (ko) | 2013-07-25 | 2018-02-22 | 바스프 에스이 | 무정형 형태의 다사티닙 염 |
KR20160023879A (ko) * | 2013-07-25 | 2016-03-03 | 바스프 에스이 | 결정질 형태의 다사티닙 염 |
CN104341410A (zh) * | 2013-08-09 | 2015-02-11 | 上海科胜药物研发有限公司 | 一种达沙替尼新晶型及其制备方法 |
CN103483289B (zh) * | 2013-09-06 | 2016-01-27 | 浙江科源化工有限公司 | 一种2-氨基-n-(2-氯-6-甲基苯基)噻唑-5-甲酰胺的合成方法 |
WO2015107545A1 (en) | 2013-12-18 | 2015-07-23 | Dharmesh Mahendrabhai Shah | Water soluble salts of dasatinib hydrate |
CZ306732B6 (cs) * | 2013-12-19 | 2017-05-31 | Zentiva, K.S. | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu |
AU2015200822A1 (en) | 2014-03-11 | 2015-10-01 | Cerbios-Pharma Sa | Process and intermediates for the preparation of dasatinib |
RU2567537C1 (ru) * | 2014-04-23 | 2015-11-10 | Олег Ростиславович Михайлов | Кристаллическая безводная дельта-модификация n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, способ ее получения и фармацевтическая композиция на ее основе |
HU231013B1 (hu) * | 2014-05-26 | 2019-11-28 | Egis Gyógyszergyár Zrt. | Dasatinib sók |
US10301302B2 (en) | 2015-06-29 | 2019-05-28 | Msn Laboratories Private Limited | Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof |
WO2017098391A1 (en) * | 2015-12-11 | 2017-06-15 | Shilpa Medicare Limited | Process for the preparation of dasatinib |
CN105474831B (zh) * | 2015-12-16 | 2017-11-17 | 湖南省西瓜甜瓜研究所 | 一种白芨裸种消毒方法 |
WO2017108605A1 (en) | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous dasatinib |
CN105503854A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种达沙替尼无水合物的新晶型物及其制备方法 |
BR112018015891A2 (pt) | 2016-02-03 | 2018-12-26 | Dr Reddys Laboratories Ltd | formas de estado sólido de dasatinib e processos para sua preparação |
WO2017144109A1 (en) | 2016-02-25 | 2017-08-31 | Remedica Ltd | Dasatinib formulation |
CN105830582B (zh) * | 2016-04-15 | 2018-05-01 | 成都大学 | 一种白及种子的快速回土培育方法 |
GB201608587D0 (en) | 2016-05-16 | 2016-06-29 | Univ Dundee | Treatment of opiod tolerance |
CN106117195A (zh) * | 2016-06-09 | 2016-11-16 | 青岛辰达生物科技有限公司 | 一种用于治疗白血病的药物达沙替尼的合成方法 |
IT201700006157A1 (it) * | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristalli di un composto antitumorale |
IT201700006145A1 (it) * | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristallo di un composto antitumorale |
JP6597727B2 (ja) | 2017-05-11 | 2019-10-30 | 東洋インキScホールディングス株式会社 | 表面保護用粘着剤および粘着シート |
AU2018297710A1 (en) * | 2017-07-07 | 2020-02-27 | Biocon Limited | Polymorphic forms of dasatinib |
HRP20221196T1 (hr) | 2017-10-05 | 2022-12-09 | Fulcrum Therapeutics, Inc. | Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019241504A1 (en) | 2018-06-15 | 2019-12-19 | Handa Pharmaceuticals, Llc | Kinase inhibitor salts and compositions thereof |
CN109369638B (zh) * | 2018-11-21 | 2020-07-07 | 山东罗欣药业集团股份有限公司 | 一种达沙替尼的制备工艺 |
CN109503568B (zh) * | 2018-12-29 | 2020-08-07 | 山东罗欣药业集团股份有限公司 | 一种达沙替尼的制备方法 |
CN112409349A (zh) * | 2019-08-20 | 2021-02-26 | 湖南华纳大药厂股份有限公司 | 激酶抑制剂及其制备、药物组合物和用途 |
IL294928A (en) | 2020-01-24 | 2022-09-01 | Nanocopoeia Llc | Amorphous solid dispersions of dasatinib and uses thereof |
GB2592680A (en) | 2020-03-06 | 2021-09-08 | Zentiva Ks | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
US11980619B2 (en) | 2021-07-28 | 2024-05-14 | Nanocopoeia, Llc | Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses |
CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3505055A (en) * | 1966-12-07 | 1970-04-07 | Uniroyal Inc | Method of controlling plant growth with carboxamidothiazoles |
US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
IL144910A0 (en) * | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
DE602004028907D1 (de) * | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
ATE481134T1 (de) * | 2004-01-21 | 2010-10-15 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
-
2005
- 2005-02-01 TW TW094103090A patent/TWI338004B/zh active
- 2005-02-04 EP EP05722772.0A patent/EP1711481B2/en active Active
- 2005-02-04 PT PT05722772T patent/PT1711481E/pt unknown
- 2005-02-04 GE GEAP20059607A patent/GEP20094804B/en unknown
- 2005-02-04 AR ARP050100427A patent/AR047533A1/es not_active Application Discontinuation
- 2005-02-04 RU RU2006131591/04A patent/RU2382039C2/ru active
- 2005-02-04 DE DE602005018601T patent/DE602005018601D1/de active Active
- 2005-02-04 KR KR1020067015839A patent/KR101310427B1/ko active IP Right Review Request
- 2005-02-04 WO PCT/US2005/003728 patent/WO2005077945A2/en active Application Filing
- 2005-02-04 NZ NZ548613A patent/NZ548613A/en unknown
- 2005-02-04 AU AU2005212405A patent/AU2005212405B2/en active Active
- 2005-02-04 PE PE2005000128A patent/PE20050691A1/es active IP Right Grant
- 2005-02-04 JP JP2006552303A patent/JP5148115B2/ja active Active
- 2005-02-04 PL PL05722772T patent/PL1711481T5/pl unknown
- 2005-02-04 AT AT05722772T patent/ATE453630T1/de active
- 2005-02-04 DK DK05722772.0T patent/DK1711481T4/da active
- 2005-02-04 IN IN6567DEN2014 patent/IN2014DN06567A/en unknown
- 2005-02-04 SI SI200530905T patent/SI1711481T2/sl unknown
- 2005-02-04 KR KR1020127021611A patent/KR20120097424A/ko not_active Application Discontinuation
- 2005-02-04 BR BRPI0507476A patent/BRPI0507476B8/pt active IP Right Grant
- 2005-02-04 CA CA2555291A patent/CA2555291C/en active Active
- 2005-02-04 ES ES05722772T patent/ES2337272T5/es active Active
-
2006
- 2006-07-27 ZA ZA2006/06242A patent/ZA200606242B/en unknown
- 2006-08-03 IL IL177280A patent/IL177280A/en active IP Right Grant
- 2006-08-24 NO NO20063780A patent/NO338049B1/no unknown
- 2006-11-23 HK HK06112879.5A patent/HK1091835A1/xx active IP Right Maintenance
-
2010
- 2010-03-19 CY CY20101100253T patent/CY1109907T1/el unknown
- 2010-03-22 HR HRP20100166TT patent/HRP20100166T4/hr unknown
-
2012
- 2012-06-06 JP JP2012129253A patent/JP2012188446A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507476B8 (pt) | monoidrato cristalino, sua composição farmacêutica e seu uso | |
BRPI0511933B8 (pt) | derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica | |
BRPI0514750A (pt) | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase | |
GEP20084367B (en) | Diazepinoindole derivatives as kinase inhibitors | |
BRPI0507067A (pt) | diamino álcoois e seu uso como inibidores de renina | |
BRPI0514731A (pt) | derivados de pirimidina | |
WO2007049041A8 (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
BRPI0508969A (pt) | compostos orgánicos | |
TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
BR112014027244A2 (pt) | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 | |
EA200700142A1 (ru) | Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
UY28804A1 (es) | Nuevas 5-acilindolinonas con contenido en alquilo, su preparación y su uso como medicamentos. | |
EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
BRPI0414548B8 (pt) | derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso | |
BRPI0512902A (pt) | derivados de ftalazina como inibidores de parp | |
BR112012032234A2 (pt) | "derivados de heteroaril imidazolona como inibidores de jak". | |
CY1116885T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
ATE431333T1 (de) | Amino-propanolderivate | |
BRPI0512986A (pt) | novos derivados de hidantoìna | |
TW200607805A (en) | Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | |
BRPI0516200A (pt) | forma cristalina do cloridrato de (3-ciano-1h-indol-7-il)-[4-(4-fluorfenetril)piperazin-1-i l]metanona | |
BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) |
|
B25G | Requested change of headquarter approved |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (C |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2514, DE 12/03/2019, QUANTO AO ITEM (71) - DEPOSITANTE.ONDE SE LE: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITEDLEIA-SE: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |